Ranbaxy gets tentative USFDA nod for generic drug

New Delhi, May 18 (UNI) Ranbaxy Pharmaceuticals Inc (RPI) today said it has received tentative approval from the US Food and Drug Administration (FDA) to manufacture and market Fexofenadine Hydrochloride tablets in doses of 30, 60, and 180 milligrams.

''We are pleased to receive this tentative approval for the drug. The product will be launched after getting final approval from the FDA,'' company's Vice-President (sales and marketing) Jim Meehan said.

Total annual market sales for Fexofenadine Hydrochloride Tablets stands at 931 million dollars.

RPI, based in Jacksonville, is a wholly-owned subsidiary of Ranbaxy Laboratories Ltd, the largest pharmaceutical company in the country.

UNI